SCHEMBL4216620

SCHEMBL4216620

CC(C)=CCc1cc(C=CC(=O)c2c(O)cc(O)cc2O)ccc1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.74
AKR1B10 O60218 1/20 0.70
AKR1B1 P15121 1/20 0.70
AKR1C3 P42330 1/20 0.70
PTGS1 P23219 1/20 0.65
PTGS2 P35354 1/20 0.65
MGAM O43451 1/20 0.61
MAOA P21397 1/20 0.61
MAOB P27338 1/20 0.61
XDH P47989 1/20 0.61
CYP19A1 P11511 1/20 0.57
MEN1 O00255 1/20 0.57
CYP3A4 P08684 1/20 0.57
MAPT P10636 1/20 0.57
CHRNA7 P36544 1/20 0.57
KMT2A Q03164 1/20 0.57
SLC5A1 P13866 6/20 0.57
SLC5A2 P31639 6/20 0.57
AKT1 P31749 1/20 0.56
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30384586 1.00 PTPN1 (0.74) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
SCHEMBL25279943 0.90 MGAM (0.63) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
SCHEMBL1659323 0.90 CYP19A1 (0.64) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
SCHEMBL25234217 0.90 MGAM (0.63) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
SCHEMBL31233320 0.90 CYP19A1 (0.64) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
Licoagrochalcone A SCHEMBL30384736 0.85 PTPN1 (1.00) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
Licoagrochalcone A SCHEMBL632907 0.85 PTPN1 (1.00) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
Licoagrochalcone A SCHEMBL632908 0.85 PTPN1 (1.00) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
Drupanin SCHEMBL3680290 0.82 AKR1C3 (1.00) PTPN1AKR1B10AKR1B1AKR1C3PTGS1
Drupanin SCHEMBL5144749 0.82 AKR1C3 (1.00) PTPN1AKR1B10AKR1B1AKR1C3PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190046469-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE KUHRTS ERIC HAUSER (US) 2019-02-14 US claimed
US-20150209307-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE KUHRTS ERIC HAUSER (US) 2015-07-30 US claimed
WO-2014025989-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE KUHRTS ERIC HAUSER (US) 2014-02-13 WO claimed
US-20140045904-A1 NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT KUHRTS ERIC HAUSER (US) 2014-02-13 US claimed
WO-2012051107-A2 NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE-EFFECT KUHRTS ERIC HAUSER (US) 2012-04-19 WO claimed
US-20090209654-A1 Prenylflavonoid Formulations BIOACTIVES, INC. 2009-08-20 US claimed
WO-2008095189-A1 METHODS AND COMPOSITIONS FOR TREATING DYSLIPIDAEMIA BIOACTIVES, INC. (US) 2008-08-07 WO claimed
EP-1909584-A2 PRENYLFLAVONOID FORMULATIONS Bioactives, Inc. (US) 2008-04-16 EP claimed
US-20070218155-A1 Methods and compositions for treating dyslipidaemia BIOACTIVES, INC. 2007-09-20 US claimed
WO-2007016578-A2 PRENYLFLAVONOID FORMULATIONS BIOACTIVES, INC. (US) 2007-02-08 WO claimed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-20230059124-A1 Novel TAS2R38 Bitter Taste Receptor Agonist BIOACTIVES INC. 2023-02-23 US disclosed
WO-2012051107-A2 NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE-EFFECT KUHRTS ERIC HAUSER (US) 2012-04-19 WO disclosed
WO-2012003515-A2 STABLE FATTY ACID-CONTAINING FORMULATIONS KUHRTS ERIC HAUSER (US) 2012-01-05 WO disclosed
US-20090209654-A1 Prenylflavonoid Formulations BIOACTIVES, INC. 2009-08-20 US disclosed
WO-2008095189-A1 METHODS AND COMPOSITIONS FOR TREATING DYSLIPIDAEMIA BIOACTIVES, INC. (US) 2008-08-07 WO disclosed
US-20070218155-A1 Methods and compositions for treating dyslipidaemia BIOACTIVES, INC. 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150209307-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE CUTA, PSEN2, PNN PTPN1 3519/4885AKR1B10 2728/4885AKR1B1 2708/4885
US-20190046469-A1 COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE CUTA, PSEN2, PNN PTPN1 3519/4885AKR1B10 2728/4885AKR1B1 2708/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B PTPN1 1308/4885AKR1B10 2495/4885AKR1B1 2220/4885
US-20230059124-A1 Novel TAS2R38 Bitter Taste Receptor Agonist TAS2R38, TAS2R8, TAS2R50 PTPN1 1257/4885AKR1B10 2774/4885AKR1B1 3410/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 PTPN1 1520/4885AKR1B10 1741/4885AKR1B1 2215/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 PTPN1 1520/4885AKR1B10 1741/4885AKR1B1 2215/4885
US-20140045904-A1 NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT NAPRT, NISCH, NAMPT PTPN1 2794/4885AKR1B10 845/4885AKR1B1 430/4885
US-20090209654-A1 Prenylflavonoid Formulations TP53, CYP46A1, HPGD PTPN1 4000/4885AKR1B10 402/4885AKR1B1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.